Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chiron Fluvirin Remediation Plan Includes Hiring Chief Microbiologist

Executive Summary

Chiron is hiring a chief microbiologist as part of the firm's remediation plan following the suspension of its license to manufacture Fluvirin at its Liverpool, England plant

You may also be interested in...



Novartis’ New Vaccine Division Takes On Evolving Market

Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said

Novartis’ New Vaccine Division Takes On Evolving Market

Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said

Chiron reduces flu vaccine production estimate

Chiron will produce 18 mil. to 26 mil. doses of its influenza vaccine Fluvirin for the 2005-06 flu season, the company said June 15. In April, the company estimated it would produce 25 mil.-30 mil. doses. The company expects FDA to inspect the facility in July to determine whether deficiencies noted in a warning letter issued in December have been resolved (1"The Pink Sheet" Dec. 20, 2004, p. 30)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel